Halozyme Therapeutics (NASDAQ:HALO) Shares Up 6.6% on Earnings Beat

Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares traded up 6.6% on Tuesday following a better than expected earnings announcement. The company traded as high as $71.86 and last traded at $70.8140. 768,395 shares changed hands during trading, a decline of 55% from the average session volume of 1,718,784 shares. The stock had previously closed at $66.41.

The biopharmaceutical company reported $1.60 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 22.69% and a return on equity of 136.12%. The company had revenue of $376.71 million for the quarter, compared to analysts’ expectations of $358.60 million. During the same period in the prior year, the company earned $1.11 earnings per share. The firm’s revenue was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS.

Halozyme Therapeutics News Summary

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Halozyme beat Q1 expectations, reporting adjusted EPS of $1.60 versus consensus of $1.54 and revenue of $376.7 million versus estimates of about $358.6 million, supported by 42% year-over-year revenue growth. Halozyme Reports First Quarter 2026 Results and Reiterates 2026 Financial Guidance
• Positive Sentiment: The company announced a new $1 billion share repurchase program and said it expects to buy back at least $400 million in 2026, which investors may view as a sign of strong cash generation and confidence in long-term prospects. HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
• Positive Sentiment: Halozyme reiterated 2026 guidance, including total revenue of $1.71 billion to $1.81 billion and non-GAAP EPS of $7.75 to $8.25, showing management still expects robust growth ahead. HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
• Neutral Sentiment: Recent analyst commentary and price-target updates remain broadly constructive, with several buy ratings and a median target around $90, which may help support sentiment but does not change the near-term fundamentals. H.C. Wainwright Bullish on Halozyme Therapeutics, Inc. (HALO) Commercial Revenue Outlook
• Negative Sentiment: One update noted the company’s FY2026 EPS guidance of $7.75 to $8.25 was slightly below the consensus estimate, and some third-party summaries also framed diluted EPS as missing expectations, which could temper enthusiasm. Halozyme Therapeutics (HALO) Reports Q1 Earnings: What Key Metrics Have to Say

Analysts Set New Price Targets

A number of brokerages have commented on HALO. Weiss Ratings downgraded Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research note on Tuesday, February 24th. TD Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, February 18th. Benchmark boosted their price objective on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, February 19th. HC Wainwright upped their price objective on Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Finally, Wall Street Zen cut Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Saturday, February 21st. Six equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $79.11.

Insider Activity at Halozyme Therapeutics

In other news, CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $63.50, for a total transaction of $635,000.00. Following the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $48,754,030. This trade represents a 1.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $63.48, for a total transaction of $103,155.00. Following the sale, the director owned 38,498 shares in the company, valued at approximately $2,443,853.04. This represents a 4.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 90,482 shares of company stock worth $6,073,942 in the last three months. 2.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Halozyme Therapeutics

Several large investors have recently bought and sold shares of the stock. Empowered Funds LLC acquired a new stake in shares of Halozyme Therapeutics in the 1st quarter worth approximately $755,000. Acadian Asset Management LLC bought a new stake in Halozyme Therapeutics during the first quarter worth approximately $195,000. Hsbc Holdings PLC raised its holdings in Halozyme Therapeutics by 117.1% during the second quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock worth $522,000 after purchasing an additional 5,448 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in Halozyme Therapeutics by 6.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 174 shares during the period. Finally, Baird Financial Group Inc. lifted its position in Halozyme Therapeutics by 6.2% in the second quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock worth $577,000 after purchasing an additional 650 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Trading Up 8.1%

The stock has a market capitalization of $8.51 billion, a P/E ratio of 28.84, a price-to-earnings-growth ratio of 0.26 and a beta of 0.89. The business has a 50 day simple moving average of $65.68 and a 200-day simple moving average of $68.57. The company has a debt-to-equity ratio of 43.89, a quick ratio of 3.66 and a current ratio of 4.66.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.